The Yin and Yang of Innate Lymphoid Cells in Cancer

Immunology Letters

Volumn 179, Issue , 2016, Pages 29-35

  Carrega, Paolo ^a,b   Campana, Stefania ^b   Bonaccorsi, Irene ^b   Ferlazzo, Guido ^b,c  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cancer; Cytokines; Innate lymphoid cells; Interferon ; Interleukin 22; Tertiary lymphoid structures

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 5; CYTOKINE;

ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER TISSUE; CARCINOGENESIS; CELL ACTIVATION; CELL ACTIVITY; CELL SUBPOPULATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOID CELL; LYMPHOID TISSUE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; TISSUE REACTION; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; CHINESE MEDICINE; CYTOLOGY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; GENETICS; IMMUNITY; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNITY; IMMUNITY, INNATE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; NEOPLASMS; TUMOR MICROENVIRONMENT; YIN-YANG;

EID: 84977655006     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2016.06.003     Document Type: Article

References (92)

1. [1] Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J.P., Eberl, G., Koyasu, S., Locksley, R.M., McKenzie, A.N., Mebius, R.E., Powrie, F., Vivier, E., Innate lymphoid cells – a proposal for uniform nomenclature. Nat. Rev. Immunol. 13 (2013), 145–149.
2. [2] Spits, H., Cupedo, T., Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 30 (2012), 647–675.
3. [3] Strowig, T., Henao-Mejia, J., Elinav, E., Flavell, R., Inflammasomes in health and disease. Nature 481 (2012), 278–286.
4. [4] Martinon, F., Mayor, A., Tschopp, J., The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27 (2009), 229–265.
5. [5] Nowarski, R., Gagliani, N., Huber, S., Flavell, R.A., Innate immune cells in inflammation and cancer. Cancer Immunol. Res. 1 (2013), 77–84.
6. [6] Zitvogel, L., Kepp, O., Galluzzi, L., Kroemer, G., Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13 (2012), 343–351.
7. [7] Sivori, S., Pende, D., Bottino, C., Marcenaro, E., Pessino, A., Biassoni, R., Moretta, L., Moretta, A., NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur. J. Immunol. 29 (1999), 1656–1666.
8. [8] Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., Bottino, C., Moretta, L., Moretta, A., Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190 (1999), 1505–1516.
9. [9] Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., Moretta, A., NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187 (1998), 2065–2072.
10. [10] Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M.C., Biassoni, R., Moretta, L., Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19 (2001), 197–223.
11. [11] Kruse, P.H., Matta, J., Ugolini, S., Vivier, E., Natural cytotoxicity receptors and their ligands. Immunol. Cell Biol. 92 (2014), 221–229.
12. [12] Pogge von Strandmann, E., Simhadri, V.R., von Tresckow, B., Sasse, S., Reiners, K.S., Hansen, H.P., Rothe, A., Boll, B., Simhadri, V.L., Borchmann, P., McKinnon, P.J., Hallek, M., Engert, A., Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27 (2007), 965–974.
13. [13] Brandt, C.S., Baratin, M., Yi, E.C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C.D., Kaifu, T., Chabannon, C., Moretta, A., West, R., Xu, W., Vivier, E., Levin, S.D., The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206 (2009), 1495–1503.
14. [14] Baychelier, F., Sennepin, A., Ermonval, M., Dorgham, K., Debre, P., Vieillard, V., Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 122 (2013), 2935–2942.
15. [15] Steinman, L., A rush to judgment on Th17. J. Exp. Med. 205 (2008), 1517–1522.
16. [16] Annunziato, F., Romagnani, C., Romagnani, S., The 3 major types of innate and adaptive cell-mediated effector immunity. J. Allergy Clin. Immunol. 135 (2015), 626–635.
17. [17] Yang, X.O., Pappu, B.P., Nurieva, R., Akimzhanov, A., Kang, H.S., Chung, Y., Ma, L., Shah, B., Panopoulos, A.D., Schluns, K.S., Watowich, S.S., Tian, Q., Jetten, A.M., Dong, C., T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28 (2008), 29–39.
18. [18] Foster, P.S., Hogan, S.P., Ramsay, A.J., Matthaei, K.I., Young, I.G., Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183 (1996), 195–201.
19. [19] Wynn, T.A., Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4 (2004), 583–594.
20. [20] Sonnenberg, G.F., Transcriptionally defining ILC heterogeneity in humans. Nat. Immunol. 17 (2016), 351–352.
21. [21] Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., Schreiber, R.D., Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 7556–7561.
22. [22] Zaidi, M.R., Merlino, G., The two faces of interferon-gamma in cancer. Clin. Cancer Res. 17 (2011), 6118–6124.
23. [23] Garbe, C., Krasagakis, K., Zouboulis, C.C., Schroder, K., Kruger, S., Stadler, R., Orfanos, C.E., Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J. Invest. Dermatol. 95 (1990), 231S–237S.
24. [24] Gorbacheva, V.Y., Lindner, D., Sen, G.C., Vestal, D.J., The interferon (IFN)-induced GTPase, mGBP-2: Role in IFN-gamma-induced murine fibroblast proliferation. J. Biol. Chem. 277 (2002), 6080–6087.
25. [25] Taniguchi, K., Petersson, M., Hoglund, P., Kiessling, R., Klein, G., Karre, K., Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc. Natl. Acad. Sci. U. S. A. 84 (1987), 3405–3409.
26. [26] Ostrand-Rosenberg, S., Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182 (2009), 4499–4506.
27. [27] Katz, J.B., Muller, A.J., Prendergast, G.C., Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222 (2008), 206–221.
28. [28] Lollini, P.L., Bosco, M.C., Cavallo, F., De Giovanni, C., Giovarelli, M., Landuzzi, L., Musiani, P., Modesti, A., Nicoletti, G., Palmieri, G., et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int. J. Cancer 55 (1993), 320–329.
29. [29] Wischhusen, J., Waschbisch, A., Wiendl, H., Immune-refractory cancers and their little helpers–an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. Semin. Cancer Biol. 17 (2007), 459–468.
30. [30] Gobin, S.J., van den Elsen, P.J., Transcriptional regulation of the MHC class ib genes HLA-E, HLA-F, and HLA-G. Hum. Immunol. 61 (2000), 1102–1107.
31. [31] Cho, H.I., Lee, Y.R., Celis, E., Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 117 (2011), 135–144.
32. [32] Munn, D.H., Bronte, V., Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39 (2016), 1–6.
33. [33] Jovanovic, I.P., Pejnovic, N.N., Radosavljevic, G.D., Pantic, J.M., Milovanovic, M.Z., Arsenijevic, N.N., Lukic, M.L., Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 134 (2014), 1669–1682.
34. [34] Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M., Ley, K., Development of monocytes, macrophages, and dendritic cells. Science 327 (2010), 656–661.
35. [35] Gordon, S., Martinez, F.O., Alternative activation of macrophages: mechanism and functions. Immunity 32 (2010), 593–604.
36. [36] Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
37. [37] Balkwill, F., Charles, K.A., Mantovani, A., Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005), 211–217.
38. [38] Qian, B.Z., Pollard, J.W., Macrophage diversity enhances tumor progression and metastasis. Cell 141 (2010), 39–51.
39. [39] Monticelli, L.A., Osborne, L.C., Noti, M., Tran, S.V., Zaiss, D.M., Artis, D., IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10762–10767.
40. [40] Zaiss, D.M., van Loosdregt, J., Gorlani, A., Bekker, C.P., Grone, A., Sibilia, M., van Bergen en Henegouwen, P.M., Roovers, R.C., Coffer, P.J., Sijts, A.J., Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 38 (2013), 275–284.
41. [41] Li, J., Razumilava, N., Gores, G.J., Walters, S., Mizuochi, T., Mourya, R., Bessho, K., Wang, Y.H., Glaser, S.S., Shivakumar, P., Bezerra, J.A., Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J. Clin. Invest. 124 (2014), 3241–3251.
42. [42] Carrega, P., Loiacono, F., Di Carlo, E., Scaramuccia, A., Mora, M., Conte, R., Benelli, R., Spaggiari, G.M., Cantoni, C., Campana, S., Bonaccorsi, I., Morandi, B., Truini, M., Mingari, M.C., Moretta, L., Ferlazzo, G., NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat. Commun., 6, 2015, 8280.
43. [43] Geremia, A., Arancibia-Carcamo, C.V., Fleming, M.P., Rust, N., Singh, B., Mortensen, N.J., Travis, S.P., Powrie, F., IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208 (2011), 1127–1133.
44. [44] Triantafillidis, J.K., Nasioulas, G., Kosmidis, P.A., Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 29 (2009), 2727–2737.
45. [45] Langowski, J.L., Zhang, X., Wu, L., Mattson, J.D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R.A., Oft, M., IL-23 promotes tumour incidence and growth. Nature 442 (2006), 461–465.
46. [46] Grivennikov, S.I., Wang, K., Mucida, D., Stewart, C.A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.Y., Osterreicher, C.H., Hung, K.E., Datz, C., Feng, Y., Fearon, E.R., Oukka, M., Tessarollo, L., Coppola, V., Yarovinsky, F., Cheroutre, H., Eckmann, L., Trinchieri, G., Karin, M., Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491 (2012), 254–258.
47. [47] Li, J., Lau, G., Chen, L., Yuan, Y.F., Huang, J., Luk, J.M., Xie, D., Guan, X.Y., Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One, 7, 2012, e46264.
48. [48] Schetter, A.J., Nguyen, G.H., Bowman, E.D., Mathe, E.A., Yuen, S.T., Hawkes, J.E., Croce, C.M., Leung, S.Y., Harris, C.C., Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin. Cancer Res. 15 (2009), 5878–5887.
49. [49] Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.H., Pages, F., Galon, J., Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 71 (2011), 1263–1271.
50. [50] Pan, B., Shen, J., Cao, J., Zhou, Y., Shang, L., Jin, S., Cao, S., Che, D., Liu, F., Yu, Y., Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci. Rep., 5, 2015, 16053.
51. [51] Zhang, J.P., Yan, J., Xu, J., Pang, X.H., Chen, M.S., Li, L., Wu, C., Li, S.P., Zheng, L., Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50 (2009), 980–989.
52. [52] Kirchberger, S., Royston, D.J., Boulard, O., Thornton, E., Franchini, F., Szabady, R.L., Harrison, O., Powrie, F., Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210 (2013), 917–931.
53. [53] Huber, S., Gagliani, N., Zenewicz, L.A., Huber, F.J., Bosurgi, L., Hu, B., Hedl, M., Zhang, W., O'Connor, W. Jr., Murphy, A.J., Valenzuela, D.M., Yancopoulos, G.D., Booth, C.J., Cho, J.H., Ouyang, W., Abraham, C., Flavell, R.A., IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491 (2012), 259–263.
54. [54] Chin, Y.E., Kitagawa, M., Su, W.C., You, Z.H., Iwamoto, Y., Fu, X.Y., Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272 (1996), 719–722.
55. [55] Hobeika, A.C., Etienne, W., Torres, B.A., Johnson, H.M., Subramaniam, P.S., IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis. J. Interferon Cytokine Res. 19 (1999), 1351–1361.
56. [56] Platanias, L.C., Uddin, S., Bruno, E., Korkmaz, M., Ahmad, S., Alsayed, Y., Van Den Berg, D., Druker, B.J., Wickrema, A., Hoffman, R., CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp. Hematol. 27 (1999), 1315–1321.
57. [57] Ruegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P., Lejeune, F.J., Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 4 (1998), 408–414.
58. [58] Coughlin, C.M., Salhany, K.E., Gee, M.S., LaTemple, D.C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J.E., Liu, L., Liao, F., Farber, J.M., Pestka, S., Trinchieri, G., Lee, W.M., Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9 (1998), 25–34.
59. [59] Beatty, G., Paterson, Y., IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J. Immunol. 166 (2001), 2276–2282.
60. [60] Chawla-Sarkar, M., Lindner, D.J., Liu, Y.F., Williams, B.R., Sen, G.C., Silverman, R.H., Borden, E.C., Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8 (2003), 237–249.
61. [61] Seliger, B., Ruiz-Cabello, F., Garrido, F., IFN inducibility of major histocompatibility antigens in tumors. Adv. Cancer Res. 101 (2008), 249–276.
62. [62] Kunz, M., Toksoy, A., Goebeler, M., Engelhardt, E., Brocker, E., Gillitzer, R., Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J. Pathol. 189 (1999), 552–558.
63. [63] Mukai, S., Kjaergaard, J., Shu, S., Plautz, G.E., Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 59 (1999), 5245–5249.
64. [64] Hu, X., Chakravarty, S.D., Ivashkiv, L.B., Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol. Rev. 226 (2008), 41–56.
65. [65] Sanderson, C.J., Warren, D.J., Strath, M., Identification of a lymphokine that stimulates eosinophil differentiation in vitro Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures. J. Exp. Med. 162 (1985), 60–74.
66. [66] Davis, B.P., Rothenberg, M.E., Eosinophils and cancer. Cancer Immunol. Res. 2 (2014), 1–8.
67. [67] Pretlow, T.P., Keith, E.F., Cryar, A.K., Bartolucci, A.A., Pitts, A.M., Pretlow, T.G. 2nd., Kimball, P.M., Boohaker, E.A., Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res. 43 (1983), 2997–3000.
68. [68] Dorta, R.G., Landman, G., Kowalski, L.P., Lauris, J.R., Latorre, M.R., Oliveira, D.T., Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 41 (2002), 152–157.
69. [69] Ishibashi, S., Ohashi, Y., Suzuki, T., Miyazaki, S., Moriya, T., Satomi, S., Sasano, H., Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res. 26 (2006), 1419–1424.
70. [70] Fujii, M., Yamashita, T., Ishiguro, R., Tashiro, M., Kameyama, K., Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx 29 (2002), 175–181.
71. [71] Ono, Y., Ozawa, M., Tamura, Y., Suzuki, T., Suzuki, K., Kurokawa, K., Fukabori, Y., Yamanaka, H., Tumor-associated tissue eosinophilia of penile cancer. Int. J. Urol. 9 (2002), 82–87.
72. [72] Costello, R., O'Callaghan, T., Sebahoun, G., Eosinophils and antitumour response. Rev. Med. Interne 26 (2005), 479–484.
73. [73] Luna-More, S., Florez, P., Ayala, A., Diaz, F., Santos, A., Neutral and acid mucins and eosinophil and argyrophil crystalloids in carcinoma and atypical adenomatous hyperplasia of the prostate. Pathol. Res. Pract. 193 (1997), 291–298.
74. [74] Nussbaum, J.C., Van Dyken, S.J., von Moltke, J., Cheng, L.E., Mohapatra, A., Molofsky, A.B., Thornton, E.E., Krummel, M.F., Chawla, A., Liang, H.E., Locksley, R.M., Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 502 (2013), 245–248.
75. [75] Gleich, G.J., Adolphson, C.R., The eosinophilic leukocyte: structure and function. Adv. Immunol. 39 (1986), 177–253.
76. [76] Caruso, R.A., Parisi, A., Quattrocchi, E., Scardigno, M., Branca, G., Parisi, C., Luciano, R., Paparo, D., Fedele, F., Ultrastructural descriptions of heterotypic aggregation between eosinophils and tumor cells in human gastric carcinomas. Ultrastruct. Pathol. 35 (2011), 145–149.
77. [77] Ikutani, M., Yanagibashi, T., Ogasawara, M., Tsuneyama, K., Yamamoto, S., Hattori, Y., Kouro, T., Itakura, A., Nagai, Y., Takaki, S., Takatsu, K., Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J. Immunol. 188 (2012), 703–713.
78. [78] Simson, L., Ellyard, J.I., Dent, L.A., Matthaei, K.I., Rothenberg, M.E., Foster, P.S., Smyth, M.J., Parish, C.R., Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol. 178 (2007), 4222–4229.
79. [79] Simon, H.U., Plotz, S., Simon, D., Seitzer, U., Braathen, L.R., Menz, G., Straumann, A., Dummer, R., Levi-Schaffer, F., Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur. J. Immunol. 33 (2003), 834–839.
80. [80] Schaefer, J.T., Patterson, J.W., Deacon, D.H., Smolkin, M.E., Petroni, G.R., Jackson, E.M., Slingluff, C.L. Jr., Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J. Transl. Med., 8, 2010, 79.
81. [81] da Silva, J.M., Queiroz-Junior, C.M., Batista, A.C., Rachid, M.A., Teixeira, M.M., da Silva, T.A., Eosinophil depletion protects mice from tongue squamous cell carcinoma induced by 4-nitroquinoline-1-oxide. Histol. Histopathol. 29 (2013), 387–396.
82. [82] Dieu-Nosjean, M.C., Antoine, M., Danel, C., Heudes, D., Wislez, M., Poulot, V., Rabbe, N., Laurans, L., Tartour, E., de Chaisemartin, L., Lebecque, S., Fridman, W.H., Cadranel, J., Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26 (2008), 4410–4417.
83. [83] Barone, F., Nayar, S., Campos, J., Cloake, T., Withers, D.R., Toellner, K.M., Zhang, Y., Fouser, L., Fisher, B., Bowman, S., Rangel-Moreno, J., Garcia-Hernandez Mde, L., Randall, T.D., Lucchesi, D., Bombardieri, M., Pitzalis, C., Luther, S.A., Buckley, C.D., IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 11024–11029.
84. [84] Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E., Becher, B., IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11 (2010), 1030–1038.
85. [85] Benchetrit, F., Ciree, A., Vives, V., Warnier, G., Gey, A., Sautes-Fridman, C., Fossiez, F., Haicheur, N., Fridman, W.H., Tartour, E., Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99 (2002), 2114–2121.
86. [86] Kryczek, I., Wei, S., Szeliga, W., Vatan, L., Zou, W., Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114 (2009), 357–359.
87. [87] Artis, D., Spits, H., The biology of innate lymphoid cells. Nature 517 (2015), 293–301.
88. [88] Moretta, L., Moretta, A., Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 23 (2004), 255–259.
89. [89] Walker, J.A., Barlow, J.L., McKenzie, A.N., Innate lymphoid cells—how did we miss them?. Nat. Rev. Immunol. 13 (2013), 75–87.
90. [90] Eberl, G., Di Santo, J.P., Vivier, E., The brave new world of innate lymphoid cells. Nat. Immunol. 16 (2015), 1–5.
91. [91] Robinette, M.L., Fuchs, A., Cortez, V.S., Lee, J.S., Wang, Y., Durum, S.K., Gilfillan, S., Colonna, M., Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16 (2015), 306–317.
92. [92] Montaldo, E., Teixeira-Alves, L.G., Glatzer, T., Durek, P., Stervbo, U., Hamann, W., Babic, M., Paclik, D., Stolzel, K., Grone, J., Lozza, L., Juelke, K., Matzmohr, N., Loiacono, F., Petronelli, F., Huntington, N.D., Moretta, L., Mingari, M.C., Romagnani, C., Human RORgammat(+)CD34(+) cells are lineage-specified progenitors of group 3 RORgammat(+) innate lymphoid cells. Immunity 41 (2014), 988–1000.